Table 2 Baseline clinical characteristics of the high and low Ki-67 expression in training and validation cohort
From: Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma
| Ā | Training (nā=ā103) | Validation (nā=ā48) | ||||||
|---|---|---|---|---|---|---|---|---|
High Ki-67 (nā=ā80) | Low Ki-67 (nā=ā23) | P values | High Ki-67 (nā=ā32) | Low Ki-67 (nā=ā16) | P values | |||
Age (years), median (IQR) | 61.0 (49.0, 67.5) | 64.0 (51.3, 70.5) | 0.292 | 54.5 (49.5, 62.0) | 57.5.4 (52.5, 70.5) | 0.116 | ||
Gender, no.(%) | Ā | Ā | 0.721 | Ā | Ā | 1.000 | ||
Ā Male | 62 (77.5) | 17 (73.9) | Ā | 27 (84.4) | 13 (81.3) | Ā | ||
Ā Female | 18 (22.5) | 6 (26.1) | Ā | 5 (15.6) | 3 (18.7) | Ā | ||
ALT,(U/L), median(IQR) | 34.3 (21.1, 46.5) | 25.0 (19.9, 38.8) | 0.207 | 34.4 (16.0, 35.9) | 49.3 (18.3, 73.1) | 0.246 | ||
AST, (U/L), median(IQR) | 33.1 (24.8, 43.3) | 30.0 (24.5, 42.5) | 0.553 | 32.1 (21.9, 35.6) | 44.1 (23.7, 65.4) | 0.341 | ||
GGT, (U/L), median(IQR) | 49.7 (30.7, 109.8) | 46.1 (30.2, 66.0) | 0.303 | 58.7 (16.0, 80.6) | 36.8 (27.0, 179.5) | 0.974 | ||
AFP, (Āµg/L), median(IQR) | 44.4 (4.5, 946.8) | 3.3 (1.9, 15.4) | 0.000 | 55.7(2.5, 199.3) | 3.8 (2.1, 19.5) | 0.006 | ||
AFP group.no(%) | Ā | Ā | 0.000 | Ā | Ā | 0.026 | ||
Ā Ā ā¤ā20Ā Āµg/L | 35 (43.8) | 19 (82.6) | Ā | 13 (40.6) | 12 (75.0) | Ā | ||
Ā Ā 20ā400Ā Āµg/L | 18 (22.5) | 3 (13.1) | Ā | 10 (31.3) | 3 (18.8) | Ā | ||
Ā Ā >ā400Ā Āµg/L | 27 (33.7) | 1 (4.3) | Ā | 9 (28.1) | 1 (6.2) | Ā | ||
Hepatitis B, no.(%) | Ā | Ā | 0.003 | Ā | Ā | 1.000 | ||
Ā Negative | 16 (20.0) | 9 (39.1) | Ā | 7 (21.9) | 4 (25.0) | Ā | ||
Ā Positive | 64 (80.0) | 14 (60.9) | Ā | 25 (78.1) | 12 (75.0) | Ā | ||
Hepatitis C, no.(%) | Ā | Ā | 0.573 | Ā | Ā | Ā | ||
Ā Negative | 76 (95.0) | 23 (100) | Ā | 31 (96.9) | 15 (93.8) | 1.000 | ||
Ā Ā Positive | 4 (5.0) | 0 (0) | Ā | 1 (3.1) | 1 (6.2) | Ā | ||
Cirrhosis, no.(%) | Ā | Ā | 0.114 | Ā | Ā | 0.499 | ||
Ā Negative | 21 (26.3) | 10 (43.5) | Ā | 7 (21.9) | 5 (31.3) | Ā | ||
Ā Positive | 59 (73.7) | 13 (56.5) | Ā | 25 (78.1) | 11 (68.7) | Ā | ||
Tumor grade, no.(%) | Ā | Ā | 0.040 | Ā | Ā | 0.040 | ||
Ā Low-grade tumor | 45 (56.3) | 19 (82.6) | Ā | 21(65.6) | 15 (93.7) | Ā | ||
Ā High-grade tumor | 35 (43.7) | 4 (17.4) | Ā | 11 (34.4) | 1(6.3) | Ā | ||